Evidence map›Paper›PMID 41240070›Full record

ReviewProtoplasma2026

Primary glioma cell culture: from monolayer to organoids.

I E Pristyazhnyuk, E V Stupak, V V Stupak, A G Menzorov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

I E PristyazhnyukDepartment of Genetics and Genetic Technologies, Sirius University of Science and Technology, Sirius, 354340, Russia. iprist@bionet.nsc.ru.ORCID http://orcid.org/0000-0003-0226-4213
E V StupakDepartment of Neurosurgery, Novosibirsk Research Institute of Traumatology and Orthopedics N.a. Ya.L. Tsivyan, Novosibirsk, 630091, Russia.
V V StupakDepartment of Neurosurgery, Novosibirsk Research Institute of Traumatology and Orthopedics N.a. Ya.L. Tsivyan, Novosibirsk, 630091, Russia.
A G MenzorovInstitute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia.

Funding

Ministry of Education and Science of the Russian Federation FWNR-2022-0019State program of the "Sirius" Federal Territory "Scientific and technological development of the 'Sirius' Federal Territory" 27.09.2024State program of the "Sirius" Federal Territory "Scientific and technological development of the 'Sirius' Federal Territory" Agreement No26-03
6 · The paper itself

Abstract

Gliomas are the most frequent tumors of the central nervous system, with an extremely low efficiency of treatment. Primary glioma cell cultures may provide an in vitro model for studying these tumors and the development of therapeutic approaches. In this review, we assess different factors that may contribute to glioma malignancy, such as the presence of glioma stem cells, cellular heterogeneity, and selection for specific genotypes. We discuss approaches for primary glioma cell culture establishment and the role of particular components of the cultivation media: culture in monolayer, neurospheres, and glioblastoma organoids; the influence of serum, growth factors, and surface coating; and the presence of glioma stem cells. Different cell culture protocols have various drawbacks - loss of the parental tumor cellular composition, loss of glioma stem cells, or loss of the glioma microenvironment. We argue that to produce primary glioma cell culture, researchers shall use a combination of standardized protocols: serum-free neurosphere culture, serum-based monolayer culture, and glioblastoma organoids.

Indexed as

Epithelial-mesenchymal transitionGlioblastoma organoidGliomaGlioma stem cellsNeurospherePrimary glioma cell culture

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.